Femasys (NASDAQ:FEMY) Now Covered by Analysts at Lake Street Capital

Lake Street Capital assumed coverage on shares of Femasys (NASDAQ:FEMY) in a report published on Tuesday,Benzinga reports. The brokerage issued a buy rating and a $1.50 price objective on the stock.

Several other equities analysts have also recently weighed in on FEMY. Wall Street Zen cut Femasys from a “hold” rating to a “sell” rating in a research note on Saturday, December 20th. Laidlaw started coverage on shares of Femasys in a research report on Thursday, November 20th. They set a “buy” rating and a $6.50 price target on the stock. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Femasys in a report on Thursday, January 22nd. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $5.50.

Femasys Trading Down 1.6%

NASDAQ FEMY opened at $0.53 on Tuesday. The company has a quick ratio of 0.61, a current ratio of 1.16 and a debt-to-equity ratio of 0.01. The business has a 50 day moving average price of $0.58 and a 200-day moving average price of $0.62. Femasys has a 52 week low of $0.31 and a 52 week high of $1.76. The company has a market cap of $30.96 million, a price-to-earnings ratio of -0.74 and a beta of -2.53.

Institutional Trading of Femasys

Several hedge funds have recently made changes to their positions in the company. Banco BTG Pactual S.A. purchased a new position in shares of Femasys during the 4th quarter valued at $88,000. Geode Capital Management LLC raised its stake in Femasys by 50.8% in the 4th quarter. Geode Capital Management LLC now owns 389,280 shares of the company’s stock valued at $224,000 after acquiring an additional 131,052 shares during the period. Jane Street Group LLC purchased a new stake in Femasys during the fourth quarter valued at about $62,000. Cetera Investment Advisers bought a new position in Femasys during the fourth quarter worth about $36,000. Finally, HRT Financial LP purchased a new position in shares of Femasys in the fourth quarter worth about $30,000. 65.27% of the stock is currently owned by institutional investors.

Femasys Company Profile

Femasys International, Inc is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.

The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography.